Literature DB >> 15369572

Early adolescent cannabis exposure and positive and negative dimensions of psychosis.

N C Stefanis1, P Delespaul, C Henquet, C Bakoula, C N Stefanis, J Van Os.   

Abstract

AIMS: To investigate the effect of exposure to cannabis early in adolescence on subclinical positive and negative symptoms of psychosis.
DESIGN: Cross-sectional survey in the context of an ongoing cohort study.
SETTING: Government-supported general population cohort study. PARTICIPANTS: A total of 3500 representative 19-year olds in Greece. MEASUREMENTS: Subjects filled in the 40-item Community Assessment of Psychic Experiences, measuring subclinical positive (paranoia, hallucinations, grandiosity, first-rank symptoms) and negative psychosis dimensions and depression. Drug use was also reported on.
FINDINGS: Use of cannabis was associated positively with both positive and negative dimensions of psychosis, independent of each other, and of depression. An association between cannabis and depression disappeared after adjustment for the negative psychosis dimensions. First use of cannabis below age 16 years was associated with a much stronger effect than first use after age 15 years, independent of life-time frequency of use. The association between cannabis and psychosis was not influenced by the distress associated with the experiences, indicating that self-medication may be an unlikely explanation for the entire association between cannabis and psychosis.
CONCLUSIONS: These results add credence to the hypothesis that cannabis contributes to the population level of expression of psychosis. In particular, exposure early in adolescence may increase the risk for the subclinical positive and negative dimensions of psychosis, but not for depression.

Entities:  

Mesh:

Year:  2004        PMID: 15369572     DOI: 10.1111/j.1360-0443.2004.00806.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  69 in total

1.  l-Theanine Prevents Long-Term Affective and Cognitive Side Effects of Adolescent Δ-9-Tetrahydrocannabinol Exposure and Blocks Associated Molecular and Neuronal Abnormalities in the Mesocorticolimbic Circuitry.

Authors:  Marta De Felice; Justine Renard; Roger Hudson; Hanna J Szkudlarek; Brian J Pereira; Susanne Schmid; Walter J Rushlow; Steven R Laviolette
Journal:  J Neurosci       Date:  2020-12-02       Impact factor: 6.167

2.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

3.  Social determinants of self-reported emotional and behavioral problems in Greek adolescents.

Authors:  Aikaterini Kapi; Alexandra Veltsista; George Kavadias; Vasso Lekea; Chryssa Bakoula
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-05-22       Impact factor: 4.328

Review 4.  Psychometric Properties of "Community Assessment of Psychic Experiences": Review and Meta-analyses.

Authors:  Winifred Mark; Timothea Toulopoulou
Journal:  Schizophr Bull       Date:  2015-07-06       Impact factor: 9.306

Review 5.  What is the mechanism whereby cannabis use increases risk of psychosis?

Authors:  Sonija Luzi; Paul D Morrison; John Powell; Marta di Forti; Robin M Murray
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

6.  Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Authors:  Berker Duman; Nilay Sedes; Bora Baskak
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

Review 7.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

8.  Predictors of a clinical high risk status among individuals with a family history of psychosis.

Authors:  Jacqueline Stowkowy; Jean Addington
Journal:  Schizophr Res       Date:  2013-04-20       Impact factor: 4.939

9.  Enhancement drugs: are there limits to what we should enhance and why?

Authors:  Morten Hesse
Journal:  BMC Med       Date:  2010-08-03       Impact factor: 8.775

10.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.